Study Group: Diovan Prescribers: Cardiologists(?)
Council Members in this Study Group: 45
Request a survey with this Study Group
Leading Experts in this Study Group
Owner
Joshua M. Feuer, MD
Joshua Feuer, MD, FACC, is a board certified Cardiologist in private practice in Santa Barbara, California. He also serves as a Consulting Cardiologist at Santa Barbara Cottage Hospital. Dr. Feuer specializes in aggressive preventive cardiology and cardiovascular risk assessment, and reduction. He has...
Cardiologist
NYU Medical Center
Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology. He has lectured frequently on such topics as...
Clinical Professor of Medicine
University of California, Los Angeles
Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA Medical Center of West Los Angeles. Dr. Streja has...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The potential market for treatment of lipids(cholesterol)continues to grow. Recent recommendations regarding potential for treatment of children as young as 8 are controversial, primarily because of the lack of data to demonstrate efficacy in terms of "hard" endpoints(i.e. mortality/MI)vs. morbidity...
Over the past 15 years there have been several long-term trials which have provided evidence that reduction of systolic pressure in an elderly population prevents the cognitive decline associated with ageing. The most recent studies have demonstrated the prevention of Alzheimer's-like symptoms. These...
Third party payers benefit the most from EHRs because it makes charts easier to audit The cost of implementing an EHR is excessive for a small practice of 2-5 physicians.
Novartis was able to show that combining tekturna with HCTZ provided significant improvement in blood pressure and did so safely. They also showed that it provides better 24 hour coverage and coverage if patients miss a dose or take it late, this is a significant improvement over its competitors...
Patients with rare malignancies, especially those with already metastatic diseases, are being treated with novel oncologic agents. However, as is being seen with many drugs, the hemodynamic consequences of these agents, in many cases a rise in blood pressure, may lead to cardiovascular consequences. ...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Partner
- Physician - Director
- Owner
- President
- Physician - Division Head
- Principal
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms